AstraZeneca pays $68.5 million in Seroquel marketing case

Share this article:

Pharmaceutical giant AstraZeneca on Thursday agreed to pay $68.5 million to settle allegations that it inappropriately marketed the drug Seroquel for off-label uses, multiple states' authorities announced.

The settlement will be split among 37 states, making it the largest multi-state settlement from a pharmaceutical company in U.S. history, according to the Bureau of National Affairs. States had charged AstraZeneca with marketing the drug, which is approved to treat schizophrenia and bipolar disorder, for use on elderly patients with dementia, among others. In the lawsuit, states also claimed the company hid the nature of the drug's side effects from healthcare providers.

AstraZeneca has denied any wrongdoing. A company spokesman said that the settlement was paid in order to “bring these matters to a close and move forward with our business of providing medicines to patients.” Last year, the company paid the U.S. a $502 million settlement in a separate case involving the marketing of Seroquel.

Share this article:

More in News

ACO bill in House would waive 3-midnight requirement for skilled nursing care

Certain Accountable Care Organizations would be able to send Medicare beneficiaries to a skilled nursing facility without a prior hospital stay under a bipartisan bill recently introduced in the House of Representatives.

Increasing staff-to-patient ratios improves nurse safety, researchers find

A law setting mandatory nurse-to-patient staffing ratios has reduced the number of workplace injuries for registered nurses and licensed practical nurses in California, according to recently published findings.

Life Care Centers takes Gold in Transitions category

Life Care Centers takes Gold in Transitions category

Life Care Centers of America has won the Gold Award in the McKnight's Excellence in Technology Awards in the Transitions category.